Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis

Overview

Journal High Blood Press Cardiovasc Prev

Specialty Cardiology & Vascular Diseases

Date 2022 Oct 26

PMID 36287359

Authors

Sadek Mostafa

Hosam Shabana

Farag Khalil

Ismail Mohamed El Mancy

Hendawy Abdel-Moety Zedan

Ahmed Elmoursi

Ibrahim Ghounim Ramadan

Saad El Deen Mohamed

Arafat Kassem

Islam Shawky Kamel

Affiliations

Soon will be listed here.

Abstract

Introduction: Hypertension represent the commonest cause of death in 2017. Hypertension is classified into two types which are primary or essential hypertension and secondary hypertension. The perindopril-amlodipine combination showed a significant effect in reduction of the elevated BP and the cardiovascular complications.

Aim: To evaluate the efficacy and safety of a fixed-dose single-pill combination of perindopril-amlodipine in hypertensive patients.

Methods: We searched PubMed, Medline, SCOPUS, and Web of Science for relevant clinical trials. Quality appraisal was evaluated according to GRADE and we assessed the risk of bias using Cochrane's risk of bias tool. We included the following outcomes: systolic blood pressure, diastolic blood pressure, pulse pressure, mean blood pressure, heart rate, cough, dizziness, headache, and peripheral edema. We performed the analysis of homogeneous data under the fixed-effects model, while analysis of heterogeneous data was analyzed under the random-effects model. We conducted a meta-regression according to the dose.

Results: We included ten clinical trials. The pooled analysis showed that there was a significant reduction of the systolic blood pressure, diastolic blood pressure, pulse plessure, mean blood pressure, and heart rate after the the perindopril-amlodipine combination (MD = 18.96 [14.32, 23.60], P < 0.0001), (MD = 11.90 [8.45, 15.35], P < 0.0001), (MD = 8.44 [6.91, 9.97], P = 0.0001), (MD = 13.07 [5.86, 20.29], P = 0.0004), and (MD = 2.93 [0.89, 4.96], P = 0.005), respectively. The results of the meta-regression revealed that the efficacy is increased by increasing the dose (P < 0.001) CONCLUSION: The use of the perindopril-amlodipine combination had a significant effect on the reduction of SBP, DBP, mean blood pressure, pulse pressure, and HR.

Citing Articles

Automated non-invasive laser speckle imaging of the chick heart rate and extraembryonic blood vessels and their response to Nifedipine and Amlodipine drugs.

Readhead C, Mahler S, Dong Z, Sato Y, Yang C, Bronner M Dev Biol. 2024; 519():46-54.

PMID: 39675502 PMC: 11750601. DOI: 10.1016/j.ydbio.2024.12.005.

Single-Pill Combination Therapy of Amlodipine, Telmisartan, and Chlorthalidone in the Management of Hypertension: A Systematic Review of Randomized Controlled Trials.

Elbardisy S, Alotaibi M, Saad A, Alhatm M, Alharbi O, Alyaqout F Cureus. 2024; 16(9):e68802.

PMID: 39371805 PMC: 11456305. DOI: 10.7759/cureus.68802.

Design, synthesis and evaluation of newer 1,4-dihydropyridine based amlodipine bio-isosteres as promising antihypertensive agents.

Takkar P, Singh B, Pani B, Kumar R RSC Adv. 2023; 13(48):34239-34248.

PMID: 38020040 PMC: 10664005. DOI: 10.1039/d3ra06387a.

Slippage of an Undeployed Stent in the Left Main Artery: A Case Report Study.

Abdelaziz A, Taleb A Heart Views. 2023; 24(3):157-159.

PMID: 37584019 PMC: 10424754. DOI: 10.4103/heartviews.heartviews_120_22.

Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis.

Almarjan A, Almarjan S, Masoud A High Blood Press Cardiovasc Prev. 2023; 30(3):207-218.

PMID: 37017901 DOI: 10.1007/s40292-023-00572-7.

References

Whelton P, Carey R, Aronow W, Casey Jr D, Collins K, Himmelfarb C . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on.... J Am Coll Cardiol. 2017; 71(19):e127-e248. DOI: 10.1016/j.jacc.2017.11.006. View

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M . [2018 ESC/ESH Guidelines for the management of arterial hypertension]. Kardiol Pol. 2019; 77(2):71-159. DOI: 10.5603/KP.2019.0018. View

Fagard R, Brguljan J, Staessen J, Thijs L, Derom C, Thomis M . Heritability of conventional and ambulatory blood pressures. A study in twins. Hypertension. 1995; 26(6 Pt 1):919-24. DOI: 10.1161/01.hyp.26.6.919. View

Streeten D, Anderson G . Secondary hypertension. An overview of its causes and management. Drugs. 1992; 43(6):805-19. DOI: 10.2165/00003495-199243060-00002. View

Hosseinnezhad A, Black R, Aeddula N, Adhikari D, Trivedi N . Glucagon-induced pheochromocytoma crisis. Endocr Pract. 2011; 17(3):e51-4. DOI: 10.4158/EP10388.CR. View

Biswas S, Dastidar D, Roy K, Pal S, Biswas T, Ganguly S . Complications of hypertension as encountered by primary care physician. J Indian Med Assoc. 2003; 101(4):257-9. View

James P, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler J . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013; 311(5):507-20. DOI: 10.1001/jama.2013.284427. View

Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J . Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005; 165(12):1410-9. DOI: 10.1001/archinte.165.12.1410. View

Turnbull F . Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003; 362(9395):1527-35. DOI: 10.1016/s0140-6736(03)14739-3. View

10.

Wald D, Law M, Morris J, Bestwick J, Wald N . Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009; 122(3):290-300. DOI: 10.1016/j.amjmed.2008.09.038. View

11.

Dimmitt S, Stampfer H . Low drug doses may improve outcomes in chronic disease. Med J Aust. 2009; 191(9):511-3. DOI: 10.5694/j.1326-5377.2009.tb02916.x. View

12.

Dahlof B, Sever P, Poulter N, Wedel H, Beevers D, Caulfield M . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm.... Lancet. 2005; 366(9489):895-906. DOI: 10.1016/S0140-6736(05)67185-1. View

13.

Bangalore S, Kamalakkannan G, Parkar S, Messerli F . Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007; 120(8):713-9. DOI: 10.1016/j.amjmed.2006.08.033. View

14.

Hamrahian S . Medication Non-adherence: a Major Cause of Resistant Hypertension. Curr Cardiol Rep. 2020; 22(11):133. DOI: 10.1007/s11886-020-01400-3. View

15.

Hurst M, Jarvis B . Perindopril: an updated review of its use in hypertension. Drugs. 2001; 61(6):867-96. DOI: 10.2165/00003495-200161060-00020. View

16.

Fares H, DiNicolantonio J, OKeefe J, Lavie C . Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart. 2016; 3(2):e000473. PMC: 5051471. DOI: 10.1136/openhrt-2016-000473. View

17.

Gradman A, Cutler N, Davis P, Robbins J, Weiss R, Wood B . Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol. 1997; 79(4):431-5. DOI: 10.1016/s0002-9149(96)00781-3. View

18.

Ojji D, Mayosi B, Francis V, Badri M, Cornelius V, Smythe W . Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans. N Engl J Med. 2019; 380(25):2429-2439. DOI: 10.1056/NEJMoa1901113. View

19.

Mancia G, Asmar R, Amodeo C, Mourad J, Taddei S, Alcocer Gamba M . Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. J Hypertens. 2014; 33(2):401-11. DOI: 10.1097/HJH.0000000000000409. View

20.

Laurent S, Parati G, Chazova I, Sirenko Y, Erglis A, Laucevicius A . Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension. J Hypertens. 2014; 33(3):653-61. DOI: 10.1097/HJH.0000000000000440. View